Chlamydia Adjuvant Accelerates Antibody Affinity Maturation

The patent applies parameter changes by modifying the chemical structure of squalene through oxidation to create isomers with different molecular configurations (epimers). These structural parameter changes result in adjuvant molecules with enhanced ability to accelerate affinity maturation and humoral immunity while maintaining vaccine efficacy. The specific oxidation products (5-epi-squalene, 6-epi-squalene, etc.) demonstrate improved performance compared to conventional adjuvants.

The patent employs self-service by designing adjuvant molecules that actively enhance the immune system's own affinity maturation processes. The oxidized squalene derivatives stimulate the immune system to naturally produce higher affinity antibodies over time, enabling vulnerable populations to achieve effective immune responses with lower vaccine dosages. The adjuvant essentially serves the immune system's need for affinity maturation acceleration without requiring external intervention in the form of higher antigen doses.

The patent applies preliminary action by pre-oxidizing squalene to create adjuvant molecules that are ready to immediately accelerate affinity maturation upon vaccination. The oxidized squalene derivatives are prepared in advance with specific molecular configurations that predispose them to effectively stimulate B-cell maturation and antibody affinity enhancement. This preliminary structural preparation enables the adjuvant to act more rapidly and efficiently during the vaccination process, reducing the time required for the immune system to develop high-affinity antibodies.